Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Contracept Reprod Health Care ; 23(3): 201-206, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29671344

RESUMEN

PURPOSE: To evaluate markers of cardiovascular disease in women with normal insulin sensitivity who had recently initiated use of depot medroxyprogesterone acetate (DMPA) as a contraceptive. MATERIALS AND METHODS: A prospective, non-randomised, comparative study. Data of 30 women of 18-40 years of age, with normal hyperinsulinaemic-euglycaemic clamp at baseline and body mass index (BMI) < 30, who opted to use DMPA or a copper intrauterine device (IUD) as a contraceptive, were analysed. Serum samples were collected for evaluation of the lipid and hepatic profile, C-reactive protein, TNF-α, interleukin-6, leptin/adiponectin ratio and free fatty acids; body composition was evaluated using DXA, blood pressure and carotid intima-media thickness were measured. Evaluations were performed at baseline and 12 months later. The groups were compared using repeated measures analysis of variance (ANOVA). Significance level was 5%. RESULTS: The mean age of the women in the DMPA and IUD group was 28.7 ± 6.5 and 28.3 ± 5.8 years, respectively; the BMI was 23.0 ± 3.4 and 24.3 ± 2.7 kg/m2, respectively, in the same groups. At 12 months, triglyceride levels were higher in the DMPA group compared to the IUD group and there was an increase in apolipoprotein B-100 in relation to baseline in DMPA group; there were no other difference between the groups. CONCLUSIONS: No clinical cardiovascular effect was found but deterioration in CV markers was observed in the first year of use of DMPA.


Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Anticonceptivos Femeninos/farmacología , Dispositivos Intrauterinos de Cobre , Acetato de Medroxiprogesterona/farmacología , Adiponectina/sangre , Adolescente , Adulto , Composición Corporal , Índice de Masa Corporal , Proteína C-Reactiva/análisis , Grosor Intima-Media Carotídeo , Femenino , Humanos , Interleucina-6/sangre , Leptina/sangre , Lípidos/sangre , Pruebas de Función Hepática , Estudios Prospectivos , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
2.
Arch Gynecol Obstet ; 294(6): 1331-1336, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27604241

RESUMEN

PURPOSE: Weight gain has been cited by women as one of the main reasons for discontinuation of the contraceptive depot medroxyprogesterone acetate (DMPA). This study aimed to evaluate binge eating and the biochemical markers of appetite in new DMPA users. METHODS: In this prospective non randomized study with adult healthy women, twenty-eight users of DMPA and twenty-five users of a copper intrauterine device (IUD) were paired for age (±1 year) and body mass index (BMI) (±1 kg/m2). We evaluated binge eating using the Binge Eating Scale (BES), the serum levels of neuropeptide Y, leptin and adiponectin, and the BMI at baseline and after 12 months in both groups. For statistical analysis was used ANOVA for to compare the means of the repeated measurements. RESULTS: Mean age was 29.6 and 28.6 years and BMI was 23.9 and 24.5 kg/m2 for the DMPA and IUD groups, respectively. After 12 months, the frequency of the scores of binge eating remained low in both groups. There were no significant differences between the groups at 12 months with respect to BMI, levels of NPY, leptin, adiponectin, and BES scores. CONCLUSIONS: Healthy adult women did not present with central stimulation of appetite or binge eating disorder in their first year after starting use of DMPA. This study reinforces the use of the contraceptive DPMA and the need for guidance related to living a healthy lifestyle for women who attribute the increase of body weight to the use of the method.


Asunto(s)
Apetito/efectos de los fármacos , Bulimia/sangre , Anticonceptivos Femeninos/farmacología , Acetato de Medroxiprogesterona/farmacología , Adiponectina/sangre , Adulto , Biomarcadores/sangre , Índice de Masa Corporal , Bulimia/tratamiento farmacológico , Preparaciones de Acción Retardada , Femenino , Humanos , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA